163 related articles for article (PubMed ID: 38107701)
1. The role of inflammatory processes and zinc levels in prostatic enlargement among Iraqi samples.
Sameen AM; Shabeeb IA; Rashied RM
J Med Life; 2023 Sep; 16(9):1388-1392. PubMed ID: 38107701
[TBL] [Abstract][Full Text] [Related]
2. Subtypes of white blood cells in patients with prostate cancer or benign prostatic hyperplasia and healthy individuals.
Cihan YB; Arslan A; Ergul MA
Asian Pac J Cancer Prev; 2013; 14(8):4779-83. PubMed ID: 24083743
[TBL] [Abstract][Full Text] [Related]
3. Role of Neutrophil to Lymphocyte Ratio or Platelet to Lymphocyte Ratio in Prediction of Bone Metastasis of Prostate Cancer.
Zhang JY; Ge P; Zhang PY; Zhao M; Ren L
Clin Lab; 2019 May; 65(5):. PubMed ID: 31115239
[TBL] [Abstract][Full Text] [Related]
4. Is the neutrophil-lymphocyte ratio an indicator of progression in patients with benign prostatic hyperplasia?
Tanik S; Albayrak S; Zengin K; Borekci H; Bakirtas H; Imamoglu MA; Gurdal M
Asian Pac J Cancer Prev; 2014; 15(15):6375-9. PubMed ID: 25124628
[TBL] [Abstract][Full Text] [Related]
5. Association between systemic inflammatory markers and serum prostate-specific antigen in men without prostatic disease - the 2001-2008 National Health and Nutrition Examination Survey.
McDonald AC; Vira MA; Vidal AC; Gan W; Freedland SJ; Taioli E
Prostate; 2014 May; 74(5):561-7. PubMed ID: 24435840
[TBL] [Abstract][Full Text] [Related]
6. Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio.
Kaynar M; Yildirim ME; Gul M; Kilic O; Ceylan K; Goktas S
Cancer Biomark; 2015; 15(3):317-23. PubMed ID: 25586096
[TBL] [Abstract][Full Text] [Related]
7. Serum monocyte fraction of white blood cells is increased in patients with high Gleason score prostate cancer.
Hayashi T; Fujita K; Tanigawa G; Kawashima A; Nagahara A; Ujike T; Uemura M; Takao T; Yamaguchi S; Nonomura N
Oncotarget; 2017 May; 8(21):35255-35261. PubMed ID: 27823973
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
[TBL] [Abstract][Full Text] [Related]
9. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.
Roehrborn CG; McConnell JD; Lieber M; Kaplan S; Geller J; Malek GH; Castellanos R; Coffield S; Saltzman B; Resnick M; Cook TJ; Waldstreicher J
Urology; 1999 Mar; 53(3):473-80. PubMed ID: 10096369
[TBL] [Abstract][Full Text] [Related]
10. [Correlation of IL-8 and IL-6 in prostatic fluid with serum prostate-specific antigen level in patients with benign prostatic hyperplasia complicated by prostatitis].
Ren X; Wu C; Yu Q; Zhu F; Liu P; Zhang H
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Jan; 36(1):135-9. PubMed ID: 26806754
[TBL] [Abstract][Full Text] [Related]
11. Predictive Value of the Platelet-To-Lymphocyte Ratio in Diagnosis of Prostate Cancer.
Yuksel OH; Urkmez A; Akan S; Yldirim C; Verit A
Asian Pac J Cancer Prev; 2015; 16(15):6407-12. PubMed ID: 26434851
[TBL] [Abstract][Full Text] [Related]
12. Association between Benign Prostatic Hyperplasia and Neutrophil-Lymphocyte Ratio, an Indicator of Inflammation and Metabolic Syndrome.
Ozer K; Horsanali MO; Gorgel SN; Horsanali BO; Ozbek E
Urol Int; 2017; 98(4):466-471. PubMed ID: 27464069
[TBL] [Abstract][Full Text] [Related]
13. Estimation levels of prostate-specific antigen, interleukin-8, oxidative stress and some inflammatory markers in sera of benign prostatic hyperplasia patients who have smoking habits as a risk factor.
Al-Barzinj RMGT
Cell Mol Biol (Noisy-le-grand); 2020 Oct; 66(7):124-130. PubMed ID: 33287932
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
[TBL] [Abstract][Full Text] [Related]
15. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.
Roehrborn CG; Boyle P; Gould AL; Waldstreicher J
Urology; 1999 Mar; 53(3):581-9. PubMed ID: 10096388
[TBL] [Abstract][Full Text] [Related]
16. Correlation between prostate volume and prostate-specific antigen in Nigerian men with symptomatic histologically-diagnosed benign prostatic hyperplasia.
Aigbe E; Irekpita E; Ogbetere FE; Alili UI
Niger J Clin Pract; 2022 Sep; 25(9):1523-1528. PubMed ID: 36149214
[TBL] [Abstract][Full Text] [Related]
17. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
18. White blood cell count is positively associated with benign prostatic hyperplasia.
Fujita K; Hosomi M; Nakagawa M; Tanigawa G; Imamura R; Uemura M; Nakai Y; Takayama H; Yamaguchi S; Nonomura N
Int J Urol; 2014 Mar; 21(3):308-12. PubMed ID: 23980666
[TBL] [Abstract][Full Text] [Related]
19. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia.
Haese A; Graefen M; Noldus J; Hammerer P; Huland E; Huland H
J Urol; 1997 Dec; 158(6):2188-92. PubMed ID: 9366341
[TBL] [Abstract][Full Text] [Related]
20. [Prostatic specific antigen (PS), pro-inflammatory cytokines, and prostatic pathology (benign prostatic hyperplasia and cancer). Relationship with malignancy].
Cansino Alcaide JR; Vera San Martín R; Rodríguez de Bethencourt Codes F; Bouraoui Y; Rodríguez Berriguete G; Oueslati R; Pérez-Utrilla M; De la Peña Barthel J; Paniagua Gómez-Alvarez R; Royuela García M
Arch Esp Urol; 2009 Jun; 62(5):359-66. PubMed ID: 19721171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
